Research reveals trigeminal ganglion interferon-γ signaling promotes orofacial neuropathic pain, suggesting a novel therapeutic strategy targeting IL-1β.
CD8⁺ T cell-derived IFN-γ activates SGCs in the TG, leading to IL-1β release that promotes neuronal hyperactivity and orofacial neuropathic pain following IONI. Targeting the IFN-γ-SGC-IL-1β signaling axis may represent a novel therapeutic strategy for orofacial neuropathic pain.
No takes yet. Share an insight, caveat, or question.
Kobayashi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: